Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
31.12
-1.41 (-4.33%)
At close: Feb 21, 2025, 4:00 PM
31.00
-0.12 (-0.39%)
After-hours: Feb 21, 2025, 7:48 PM EST
Avidity Biosciences Employees
Avidity Biosciences had 253 employees as of December 31, 2023. The number of employees increased by 67 or 36.02% compared to the previous year.
Employees
253
Change (1Y)
67
Growth (1Y)
36.02%
Revenue / Employee
$39,988
Profits / Employee
-$1,108,648
Market Cap
3.71B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 253 | 67 | 36.02% |
Dec 31, 2022 | 186 | 61 | 48.80% |
Dec 31, 2021 | 125 | 54 | 76.06% |
Dec 31, 2020 | 71 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
RNA News
- 1 day ago - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 6 weeks ago - Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 - PRNewsWire
- 2 months ago - Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases - Seeking Alpha
- 3 months ago - Avidity Biosciences to Participate in Upcoming Investor Conference - PRNewsWire
- 3 months ago - Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - PRNewsWire
- 3 months ago - Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - PRNewsWire
- 4 months ago - Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PRNewsWire
- 5 months ago - Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases - Benzinga